MaxCyte, Inc. Director/PDMR Shareholding (9375V)
27 July 2018 - 2:33AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 9375V
MaxCyte, Inc.
26 July 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Person Closely Associated Dealing
Maryland, USA, 26 July 2018 - MaxCyte (LSE: MXCT, MXCR) the
global cell-based medicines and technology company, announces that
Karin Johnston, wife of John Johnston, Non-Executive Director of
the Company, has bought 11,500 shares of common stock of 0.1 pence
each in the capital of the Company ("Common Stock") at a price of
240 pence per Common Stock.
Following this purchase, John Johnston has a beneficial interest
of 86,500 Common Stock, representing 0.2% of the issued share
capital of the Company and a further 64,800 options over Common
Stock.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Karin Johnston
====================================== ========================================
2 Reason for the notification
================================================================================
a) Position/status Person closely associated
====================================== ========================================
b) Initial notification/Amendment Initial notification
====================================== ========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
================================================================================
a) Name MaxCyte, Inc.
====================================== ========================================
b) LEI 54930053YHXULRFCU991
====================================== ========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
================================================================================
a) Description of Purchase of Common Stock
the financial
instrument, type
of instrument
====================================== ========================================
b) Identification US57777K1060
Code
====================================== ========================================
c) Nature of the Purchase of Common Stock by a person
transaction closely associated
====================================== ========================================
d) Price(s) and volume(s) Price(s) Volume(s)
====================================== =========================== ===========
240.00 pence 11,500
======================================================================= ===========
e) Aggregated information N/A (Single Transaction)
- Aggregated volume 11,500
- Price 240.00
====================================== =============================================
f) Date of the transaction 26 July 2018
====================================== ========================================
g) Place of the transaction London Stock Exchange, AIM Market
====================================== ========================================
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl, Freddy Crossley, Ryan McCarthy
(Corporate Finance)
James Stearns (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Sukaina Virji
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology to
enable its partners across the biopharmaceutical industry to
advance the development of innovative medicines, particularly in
cell therapy, including gene editing and immuno-oncology. The
Company has placed its cutting-edge flow electroporation
instruments worldwide, including with nine of the top 10 global
biopharmaceutical companies, and has more than 55 partnered
programme licenses in cell therapy including more than 25 licensed
for clinical use. With its robust delivery technology, MaxCyte
helps its partners to unlock the full potential of their
products.
For more information, visit www.maxcyte.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAKXKADAPEFF
(END) Dow Jones Newswires
July 26, 2018 12:33 ET (16:33 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024